Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | PER2 | O15055 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406066 | 0.85 | HTR1A (0.52) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL5494327 | 0.78 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7514125 | 0.76 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL30520820 | 0.76 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL21389248 | 0.76 | L3MBTL1 (0.62) | ALDH1A1MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL22662833 | 0.75 | SMN1; SMN2 (0.53) | ALDH1A1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL6699936 | 0.75 | GLS (0.71) | NPC1RAB9AMAPTSMN1; SMN2GLS | |
| SCHEMBL24796112 | 0.75 | ALDH1A1 (0.56) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL21383938 | 0.75 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ALMNAGAA | |
| SCHEMBL2947327 | 0.74 | ALDH1A1 (0.51) | ALDH1A1NPC1RAB9ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3768294-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | ALDH1A1 3305/4885NPC1 1890/4885RAB9A 664/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | ALDH1A1 3367/4885NPC1 1936/4885RAB9A 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.